Without a family history of XLH, diagnosis (even when rickets symptoms are recognized) carries its own frustration. Without experience in this unusual disorder, it is not unheard of for a physician to not even diagnose a child of an XLH parent until much later than it could be, putting bowing off to "bulky diapers" or saying "all toddlers legs are bowed" rather than even x-raying the child for rickets, or comparing the child's blood phosphorus level to an adult reference range since not all labs report the higher ranges seen in normally growing children.
XLH occurs probably in only one birth out of 20,000, so a pediatrician or general practitioner may never see it in his or her career. Even if he does diagnose the child with rickets, he might not know about XLH and presume it to be due to lack of enough vitamin D and try that first. However, XLH resists typical Vitamin D therapy, so a patient might then be put through a complete series of tests, X-rays, and consultations with specialists and then might not be diagnosed with XLH until age 3 or 4.
Precious treatment time is lost, so it's important to find a specialist with experience in this area when symptoms are first observed. This type of specialist is generally an endocrinologist or nephrologist, but specifically one with an interest in metabolic bone disorders as opposed to more routine endocrine or nephrology issues. Very few have experience in rare metabolic bone disorders, so it's important to make sure the one you see does.
If there's a family history of XLH, it should be easier to diagnose before symptoms of rickets even develop, but it's extremely important to compare lab results for serum phosphorus levels to normal levels for children of the same age, which some labs do not report. In fact, the lab may not even indicate that the reference range is suitable only for adults, so a physician inexperienced with XLH may not realize the child's results are abnormal. This causes an unnecessary delay in diagnosis.
Specialists who have several XLH patients, however, might diagnose a patient without much difficulty and know what tests to run to differentiate between the different disorders that cause rickets and osteomalacia. The earlier the diagnosis, the earlier therapy can begin, and the better the results are likely to be.
There are several phosphate wasting disorders that cause similar symptoms to XLH, so it's important to know which one the patient has since treatment for one might not be correct for another.
People with Autosomal Dominant Hypophosphatemic Rickets can have symptoms that differ only in subtle ways from those experienced by people with XLH. ADHR, as indicated by its name, is another dominantly inherited hypophosphatemic disorder, but it is caused by a different gene found on a dfferent chromosome than XLH. Its symptoms can first occur in people of any age, and in some cases its symptoms have even been found to resolve on their own.
And, certain very rare tumors [known by the names Tumor-Induced Osteomalacia (TIO) and Oncogenic Hypophosphatemic Osteomalacia (OHO)] or rare cases of giant nevus sebaceous (certain very large birthmarks, which may be related to TIO) may also cause bone problems due to hypophosphatemia. These disorders are not considered to be hereditary.
Source: The XLH Network Board of Directors
© 2011, The XLH Network Inc.
The authors of this web site are not medical professionals, and this information does not substitute for medical care. Information on these pages is based on biomedical research, published in peer-reviewed journals, and international research conferences. Additionally, in some cases anecdotal information is provided by subscribers of the F-HYPDRR group, a mailing list for The XLH Network Inc. A listing of XLH research is available. Please read our full disclaimer.
- Advocacy with ASBMR
- It's easy to think of politicians as ignorant or foolish or self-aggrandizing, and I'm about as cynical as anyone, so I was pleasantly surprised by the experience of visiting Capitol Hill to advocate for sustained funding for basic science research at Nat…
- New NIH Research Study
- NIH Research Study: Open-label Dose-titration Study of the Tolerability and Efficacy of Cinacalcet to Treat Fibroblast Growth Factor 23 (FGF23)-mediated HypophosphatemiaPrincipal Investigator: Dr. Rachel Gafni, MDSponsoring Institute: Craniofaci…
- Rare Disease Week
- The last day of February each year is World Rare Disease Day. This year, it falls on February 28th.Here in the U.S., several medical-professional and patient-support groups have gotten together to make the entire week into a time of awareness and advocacy…
- The Social Media Flashlight: How Facebook Demystified XLH
- We have another guest post today, this time from Jennifer West. She's the mother of an XLHer, who lives and works in the Wisconsin Northwoods. She's also an antique-collector and nature-lover. 2009 was one crazy year. Our youngest child was born, and…